RxDoctor Payments DataLook up a doctor →

Sixto Medina, MD

Internal Medicine · Bayamon, PRNPI 1982151585

Payments from drug & device makers

$14,705in general payments, 2019–2025

Across 680 payments — averaging $21.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • Novo Nordisk$2K
  • Lilly USA, LLC$2K
  • GSK$1K
  • Pfizer$1K
  • Boehringer Ingelheim$523
  • plus $4K from 33 others

What the payments were for

  • Food & beverage$14,670100%
  • Education$350%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,705 in reported general payments places this provider in the 95th percentile of 1,043 internal medicine providers in Puerto Rico.

See all internal medicine providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$14,977
Medicare patients
49
Services billed
282

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide208$371,009
MounjaroTirzepatide99$185,706
TrulicityDulaglutide67$115,513
Trelegy ElliptaFluticasone/Umeclidin/Vilanter172$111,668
JardianceEmpagliflozin61$96,178
EliquisApixaban54$68,233
FarxigaDapagliflozin Propanediol31$42,688
Breztri AerosphereBudesonide/Glycopyr/Formoterol63$42,076
XareltoRivaroxaban29$33,138
RybelsusSemaglutide14$22,060
Tresiba Flextouch U-100Insulin Degludec14$15,099
Breo ElliptaFluticasone/Vilanterol29$13,760
InvokanaCanagliflozin17$9,882
LinzessLinaclotide14$8,987
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen136$5,465

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$2,240$393,068222 claims
Lilly USA, LLCMounjaro, Trulicity$1,661$301,218166 claims
GSKTrelegy Ellipta, Breo Ellipta$1,331$125,428201 claims
Boehringer IngelheimJardiance$523$96,17861 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$3,374$89,551115 claims
PfizerEliquis$1,317$68,23354 claims
Johnson & JohnsonXarelto, Invokana$198$43,02046 claims
AbbVieLinzess, Synthroid$342$11,67048 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,043 internal medicine providers in Puerto Rico.

Other internal medicine in Bayamon

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →